• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Media Articles

Explore insightful coverage and perspectives on Syngene from various media outlets.
New modalities drive CDMO growth
18th May, 2025
Rethinking Growth Promoters Through the Lens of Green Chemistry
14th May, 2025
25 Transformative Years of Biosimilars
2nd May, 2025
Syngene collaborates with biotech firm to develop bile acid modulator for cholestatic disease treatment
22nd Apr, 2025
Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr
13th Apr, 2025
PROTACs: Current Landscape and Their Significance in Drug Discovery
27th Mar, 2025

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details